Mark Levick, MD PhD and Andrew Roberts, MSc MBA are seasoned pharmaceutical professionals with proven track records in drug development from molecule to market: as drug developers, global team leaders and C-suite executives. They have experience in both Big Pharma and Small Biotech in the US and Europe. They combine scientific training, regulatory insights and business experience with expertise in team coaching, which together drive high-value outcomes for companies. Mark and Andrew work with a network of trusted and experienced colleagues to deliver Thaxton Philip Consulting services to clients worldwide.
Mark Levick, MD PhD
Partner
Mark Levick is a former EU medicines regulator and CEO of a NASDAQ-listed biopharmaceutical company. Mark’s expertise was gained through leading global R&D groups at GlaxoSmithKline and Novartis in the UK, US and Switzerland. Mark provides scientific advice, due diligence, consulting and board advisory for biotech start-ups, venture capital firms, portfolio companies, pharmaceutical SME's, as well as investment, financial and legal firms.
​
Mark has a proven track record in drug development, with 13 global marketing approvals under his belt, including five first-in-class molecules and two approvals arising from successful proof-of-concept programs, which have together created more than $3bn of portfolio value over the past five years alone. Mark's career has focused on developing complex biopharmaceuticals such as monoclonal antibodies, engineered proteins, cell-based therapies, and other novel platforms. Mark's expertise includes translational science, clinical pharmacology, clinical development, technical operations and regulatory affairs. Mark is a qualified executive coach who coaches executive clients, in addition to lecturing in coaching at the University of Cambridge. Mark is experienced in helping senior leadership teams to connect the scientific and people aspects of innovation. ​
​
Before joining industry, Mark was a specialist physician practising in hospitals in Australia and the UK. Mark earned his medical degree from the University of Newcastle, Australia, and he holds a PhD in vaccine development from the University of Cambridge. Mark has received several awards and authored peer-reviewed papers in the fields of vaccine and drug development. Mark is a Fellow of the Royal College of Pathologists of Australasia and affiliated with the Faculty of Pharmaceutical Medicine in the Royal College of Physicians in the UK.
Andrew Roberts, MSc MBA
Partner
Andrew Roberts is a former pharmaceutical industry executive having served in C-suite biotech and senior pharmaceutical company roles. Andrew's experience spans many areas of the industry, including early research and translational medicine, clinical development, device development, and portfolio and board-level strategy for companies with both small molecule and biologic assets.
​
​
Andrew specializes in the intersection of R&D, Commercial, Manufacturing, Finance, Legal and Strategy and how to optimize activities to support long-term success. He also has extensive experience in organizational transformation and building, including preparing organizations for public listing. Andrew provides scientific advice, due diligence, organizational structure and governance, M&A and board advisory services for biotech start-ups, venture capital firms, portfolio companies, pharmaceutical SMEs, and firms that support investments in such organizations.
​
​
Andrew's experience has been built in organizations based in the US and Europe, including Novartis, Biogen Idec and Alvotech, and he has extensive experience working in Asia and South America as well. He has supported global marketing approval for over 20 assets, including small molecules, novel biologics and biosimilars. His passion is optimizing science and business, using his degrees in Biology from Louisiana State University and an Executive MBA from INSEAD in Paris.
Our Mission
Purpose led service, for inspired outcomes
Thaxton Philip Consulting is passionate about creating a unique life sciences consulting offering that brings together the science of drug development with the science of teams. The outcome is inspired and purpose-led R&D teams that transform molecules into life-changing drugs through great teamwork.